石药(01093.HK)受制百天线倒跌12%失15元 获利盘涌现
建议於沪科创板上市的石药集团(01093.HK)首季多赚近22%大行绩後维持看好,但公司指受累於新冠肺炎疫情影响,期内销售收入及核心利润增长均低於预期。该股承过去三连涨势,今早逆市高开见17.12元遇阻,未能企稳百天线(17.03元),获利盘涌现,股价掉头一举跌破20天、50天、10天及牛熊线(15.62-16.23元),最低见14.82元,现造14.9元,急吐12%,为最伤蓝筹,成交达6,879万股,已接近昨天全日成交量7,938万股。
石药昨午公布,首季纯利按年升21.8%至11.59亿元人民币(下同),毛利按年升近18%至45.29亿。期内,总营收按年升11.5%至61.25亿元,其中成药收入按年升18.3%至50.22亿元。里昂及瑞信绩後重申「买入」及「跑赢大市」评级,分别看20.46元及19.88元。
人大今天表决「港版国安法」,美国扬言会采取行动回应。恒指跌幅扩至332点或1.4%报22,968,成交额599亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.